Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Adynxx Inc ADYX

Healthcare Biotechnology
Adynxx, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of a new class of therapeutics called transcription factor decoys and bringing to market disease-modifying products to address unmet needs in the treatment of pain and inflammation. The Company has leveraged its AYX platform of proprietary transcription factor decoys to identify and develop... see more

Recent & Breaking News (GREY:ADYX)

Adynxx Reports Third Quarter 2019 Financial Results

GlobeNewswire November 14, 2019

Adynxx Receives NIH HEAL Initiative Funding Award for Development of Second Non-Opioid Pain Therapeutic

GlobeNewswire October 2, 2019

Adynxx Reports Second Quarter 2019 Financial Results

GlobeNewswire August 14, 2019

Adynxx Adds Gregory J. Flesher to Board of Directors, Completes Up-listing to OTCQB Market

GlobeNewswire July 22, 2019

Adynxx Stock to Move to OTC Market Following Receipt of Nasdaq Delisting Notice

GlobeNewswire June 12, 2019

Adynxx Announces Payment Date of Special Cash Dividend Previously Announced by Alliqua BioMedical

GlobeNewswire May 10, 2019

Adynxx, Inc. Receives Nasdaq Notice of Delisting or Failure to Satisfy an Initial Listing Rule or Standard

GlobeNewswire May 9, 2019

Adynxx Completes Merger with Alliqua BioMedical, Adds Pierre Legault and Matt Ruth to Board of Directors

GlobeNewswire May 6, 2019

Alliqua BioMedical Declares Contingent Special Dividend of $1.05 per Share and Announces Record Date for the Contingent Special Dividend and the Spin-Off of Contract Manufacturing Business

GlobeNewswire April 11, 2019

Alliqua Biomedical CEO Provides Update to Shareholders

GlobeNewswire January 3, 2019

New Research: Key Drivers of Growth for Zillow Group, Woodward, Navistar International, Multi-Color, Ferrellgas Partners, and Alliqua BioMedical — Factors of Influence, Major Initiatives and Sustained Production

GlobeNewswire December 27, 2018

Thinking about buying stock in Apple, Alliqua BioMedical, Inc., Advanced Micro Devices, Dollar Tree, Inc. or New Age Beverages Corp.?

PR Newswire November 29, 2018

Alliqua BioMedical to spin off and merge its Contract Manufacturing Business with TO Pharmaceuticals LLC to Create an Independent, Publicly Traded Company focused on Cannabinoid-Based Pharmaceutical Therapies

GlobeNewswire November 28, 2018

Consolidated Research: 2018 Summary Expectations for Green Brick Partners, Alliqua BioMedical, Buckle, DaVita, CDK Global, and Mylan N.V — Fundamental Analysis, Key Performance Indications

GlobeNewswire October 29, 2018

Alliqua BioMedical Inc. and Adynxx, Inc. Announce Merger Agreement to Create NASDAQ-listed Clinical-Stage Pharmaceutical Company with a Focus on Pain and Inflammation

GlobeNewswire October 12, 2018

Investor Expectations to Drive Momentum within Gorman-Rupp, Mistras Group, Inovalon, Johnson Controls International plc, Best Buy Co., and Alliqua BioMedical — Discovering Underlying Factors of Influence

GlobeNewswire June 11, 2018

Alliqua BioMedical, Inc. Announces Closing Asset Sale to Celularity Inc.

GlobeNewswire May 7, 2018

SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Investors Heritage Capital Corporation - IHRC

PR Newswire February 1, 2018

Analysis: Positioning to Benefit within Alliqua BioMedical, Donegal Group, QAD, ManpowerGroup, Acorda Therapeutics, and Arena Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results

GlobeNewswire January 31, 2018

22 Stocks Moving In Monday's Pre-Market Session

Benzinga.com  January 8, 2018